NaMi Diagnostics Announces Provisional Patent Filing for Cell Geometry Assessment Platform to Detect Unhealthy Patient Conditions
Lubbock, TX – [02/19/26] NaMi Diagnostics LLC, a pre-clinical stage biotechnology company developing rapid, cell-based diagnostics for early sepsis detection, today announced the filing of a provisional patent application titled “System, Method and Computer Program Product for Determining an Unhealthy Condition of a Patient Based on Geometric Parameter Data of Cells.” This provisional patent reflects a key milestone in advancing our Electro-Deformation Spectroscopy (EDS) platform and underscores the strength of our collaboration with Florida Atlantic University (FAU).”
The patented technology leverages advanced analysis of cellular geometric parameters—such as size, shape, and deformability—to identify early signs of disease. The system combines a proprietary EDS system with data-driven algorithms to extract geometric features from individual cells and correlate them with patient health status. This approach provides a rapid, label-free, high-throughput diagnostic solution for patient stratification, with great potential for ER ad ICU deployment. By quantifying subtle changes in mechanical properties of immune cells, we can gain meaningful insights about the host inflammatory response to infection, offering a simple yet effective way to detecting conditions such as sepsis at an early stage.
NaMi Diagnostics is currently launching for its first clinical study in collaboration with FAU and St. Mary’s Medical Center in West Palm Beach, with the goal of validating the technology for early sepsis detection in real-world clinical settings.
NaMi Diagnostics Files Provisional Patent for “Biomechanical Sepsis Detection” in Collaboration with Texas Tech University
Lubbock, TX — [01/16/26] — NaMi Diagnostics LLC, a pre-clinical stage biotechnology company developing rapid, cell-based diagnostics for rapid detection of sepsis, today announced the filing of a provisional patent application entitled “Biomechanical Sepsis Detection” in collaboration with Texas Tech University (TTU).
The patent application covers novel methods and systems for detecting sepsis and related immune dysregulation by quantifying biomechanical and biophysical signatures of immune cells. The technology combines an advanced microfluidic platform with a high-throughput imaging module to enable objective, data-driven assessment of leukocyte deformability and the activation status of the host immune system. This approach has strong potential to improve sepsis diagnosis and risk stratification in emergency and intensive care settings.
Sepsis is a life-threatening condition caused by dysregulated and overwhelming immune responses to infection and remains a leading cause of in-hospital mortality, imposing a significant healthcare burden. Rapid and accurate identification of patients at high risk of sepsis continues to be a critical unmet clinical need. To address this challenge, NaMi’s approach uniquely focuses on measuring changes in immune cell properties rather than relying solely on traditional biochemical markers and blood culture workflows.
This patent filing represents a major milestone in protecting the core intellectual property underlying our diagnostic platform. NaMi Diagnostics is currently advancing prototype development, regulatory readiness, and pre-clinical validation while preparing to launch its first pilot clinical trial in Q1 2026.
NaMi Diagnostics Selected as Winner of the TTU Innovation Hub Accelerator Program
Lubbock, TX – [04/11/25] NaMi Diagnostics LLC, has been selected as a winner of the Texas Tech University Innovation Hub Accelerator Program (Cohort 9). This recognition underscores NaMi’s strong commercialization potential and the clinical significance of rapid diagnostics that improve clinical outcomes for patients with life-threatening infections such as sepsis.
The TTU Accelerator Program provides up to $25,000 in funding, along with professional mentoring, access to university resources, and business development support to help startups accelerate innovative technologies from the laboratory to the marketplace. NaMi Diagnostics plans to use this support to drive business growth and further develop its second-line cell-deformability cytometry technology in partnership with Texas Tech University (TTU) and Texas Tech University Health Science Center (TTUHSC).
The TTU Innovation Hub Accelerator Program is designed to foster high-impact technology startups with strong commercialization and societal potential. Past participants have gone on to secure external grants, industry partnerships, and private investments, reflecting the Hub’s role as a catalyst for regional innovation and economic development. For more information, visit www.depts.ttu.edu/research/research-park/.
NaMi Diagnostics Signs Sponsored Research Agreement to Validate EDS Technology for Rapid Sepsis Detection
Lubbock, TX – [03/01/25] NaMi Diagnostics LLC, announced today that it has entered into a Sponsored Research Agreement (SRA) with Florida Atlantic University (FAU) to validate its proprietary Electro-Deformation Spectroscopy (EDS) technology for early sepsis detection (https://www.fau.edu/research/research-daily/2025/from-prototype-to-partnership/).
Under this collaboration, NaMi Diagnostics and the researcher team from the Department of Ocean & Mechanical Engineering at FAU will conduct a series of in-vitro studies to assess the analytical performance and diagnostic potential of the EDS platform in assessing alternations in immune cell deformability associated with sepsis. These changes serve as sensitive indicators of host immune activation and systemic inflammation—offering a unique, label-free approach to detect sepsis within minutes from a small blood sample. The research aims to generate key pre-clinical data supporting NaMi’s upcoming clinical development phase and future regulatory submissions.
This SRA lays the foundation for NaMi Diagnostics’ upcoming collaboration with St. Mary’s Medical Center (West Palm Beach, FL), where additional validation and pilot clinical studies are planned. Together, these initiatives advance NaMi’s mission to deliver fast, accurate, and effective sepsis diagnostics at the point of care.
NaMi Diagnostics Receives Texas Tech University President’s Innovative Startup Award
Lubbock, TX – [09/15/24] NaMi Diagnostics LLC, has been selected to receive the Texas Tech University (TTU) President’s Innovative Startup Award. This award recognizes emerging companies that demonstrate strong innovation and high commercialization potentials.
The President’s Innovative Startup Award provides $25,000 grant to support businss operations, boost R&D and marketing activities, and facilitate technology translation from research to market. This recognition highlights NaMi Diagnostics’ efforts in developing rapid, cell-based diagnostic technologies to improve clinical decision-making and patient outcomes in sepsis care.
NaMi Diagnostics Receives SBIR Award from the National Institutes of Health
Lubbock, TX [06/14/23] NaMi Diagnostics LLC, is proud to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH).
The award will support the development of NaMi’s proprietary nanoparticle-enabled biosensor, an innovative technology designed to rapidly assess specific cell expression as early biomarkers of sepsis. By providing clinicians with near real-time insights into the host immune response, our technology aims to significantly improve early diagnosis and treatment decisions for patients with suspected sepsis — a life-threatening condition that affects over 1.7 million adults in the U.S. each year.
“This NIH support marks a major milestone for NaMi Diagnostics,” said Ke Liu, Ph.D., CEO and Founder of NaMi Diagnostics. “The funding will accelerate our efforts to advance biosensor validation and clinical feasibility studies, bringing us closer to delivering a transformative diagnostic tool for critical and intensive care settings.”
The project will be conducted in collaboration with researchers at Texas Tech University (TTU), combining expertise in nanotechnology, biosensing, cell biology, and analytical chemistry.